GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurobiological Technologies Inc (OTCPK:NTII) » Definitions » Sloan Ratio %

Neurobiological Technologies (Neurobiological Technologies) Sloan Ratio % : 93.45% (As of Sep. 2009)


View and export this data going back to 1994. Start your Free Trial

What is Neurobiological Technologies Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Neurobiological Technologies's Sloan Ratio for the quarter that ended in Sep. 2009 was 93.45%.

As of Sep. 2009, Neurobiological Technologies has a Sloan Ratio of 93.45%, indicating earnings are more likely to be made up of accruals.


Neurobiological Technologies Sloan Ratio % Historical Data

The historical data trend for Neurobiological Technologies's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurobiological Technologies Sloan Ratio % Chart

Neurobiological Technologies Annual Data
Trend Jun00 Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -235.26 -162.86 -28.07 37.37 92.60

Neurobiological Technologies Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.16 18.94 30.63 92.60 93.45

Competitive Comparison of Neurobiological Technologies's Sloan Ratio %

For the Biotechnology subindustry, Neurobiological Technologies's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurobiological Technologies's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neurobiological Technologies's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Neurobiological Technologies's Sloan Ratio % falls into.



Neurobiological Technologies Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Neurobiological Technologies's Sloan Ratio for the fiscal year that ended in Jun. 2009 is calculated as

Sloan Ratio=(Net Income (A: Jun. 2009 )-Cash Flow from Operations (A: Jun. 2009 )
-Cash Flow from Investing (A: Jun. 2009 ))/Total Assets (A: Jun. 2009 )
=(3.123--16.429
--3.283)/24.66
=92.60%

Neurobiological Technologies's Sloan Ratio for the quarter that ended in Sep. 2009 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2009 )
=(11.29--11.061
--5.479)/29.782
=93.45%

Neurobiological Technologies's Net Income for the trailing twelve months (TTM) ended in Sep. 2009 was -7.838 (Dec. 2008 ) + -0.431 (Mar. 2009 ) + 14.154 (Jun. 2009 ) + 5.405 (Sep. 2009 ) = $11.29 Mil.
Neurobiological Technologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2009 was -4.946 (Dec. 2008 ) + -3.384 (Mar. 2009 ) + -5.087 (Jun. 2009 ) + 2.356 (Sep. 2009 ) = $-11.06 Mil.
Neurobiological Technologies's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2009 was -14.263 (Dec. 2008 ) + 2.479 (Mar. 2009 ) + 7.308 (Jun. 2009 ) + -1.003 (Sep. 2009 ) = $-5.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurobiological Technologies  (OTCPK:NTII) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2009, Neurobiological Technologies has a Sloan Ratio of 93.45%, indicating earnings are more likely to be made up of accruals.


Neurobiological Technologies Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Neurobiological Technologies's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurobiological Technologies (Neurobiological Technologies) Business Description

Traded in Other Exchanges
N/A
Address
2010 Crow Canyon Place, Suite 100, San Ramon, CA, USA, 94583
Neurobiological Technologies Inc is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.
Executives
Ariel Warszawski 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Ryan Heslop 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Management Co Gp, Llc 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Fvp Gp, Llc 10 percent owner C/O FIREFLY VALUE PARTNERS, LP, 551 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10176
Firefly Value Partners, Lp 10 percent owner 426 PINEVILLE ROAD, UNIT 1, NEWTOWN PA 18940
Fvp Master Fund Lp 10 percent owner FVP GP LLC, 551 FIFTH AVENUE, 36TH FLOOR, New York NY 10176
John B Stuppin director
Abraham E Cohen director 500 SEVENTH AVE 10TH FL, C/O AXONYX INC, NEW YORK NY 10018
Abraham D Sofaer director HOOVER INSTITUTION, STANFORD UNIVERSITY, STANFORD CA 94305-6010
Biotechnology Value Fund L P other: Direct Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: Direct Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Investments Llc other: Direct Beneficial Owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104

Neurobiological Technologies (Neurobiological Technologies) Headlines